ArticleFrontiers in genetics2022

Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma.

Salem Baldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.